艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06660 艾美疫苗

交易中 09-01 11:10:07

1.705

-0.005

-0.29%

最高1.710	最低1.700	成交量6.58万
今开1.700	昨收1.710	日振幅0.58%
总市值20.91亿	流通市值8.66亿	总股本12.27亿
成交额11.24万	换手率0.01%	流通股本5.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06660","market":"HK","secType":"STK","nameCN":"艾美疫苗","latestPrice":1.705,"timestamp":1788232149194,"preClose":1.71,"halted":0,"volume":65800,"delay":0,"changeRate":-0.0029239766081870723,"floatShares":507673711,"shares":1226562599,"eps":-0.55,"marketStatus":"交易中","change":-0.005,"latestTime":"09-01 11:10:07","open":1.7,"high":1.71,"low":1.7,"amount":112413,"amplitude":0.005848,"askPrice":1.71,"askSize":1400,"bidPrice":1.705,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-0.614178,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788235200000},"marketStatusCode":2,"adr":0,"listingDate":1664985600000,"exchange":"SEHK","adjPreClose":1.71,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":0.281651,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06660","defaultTab":"news","newsList":[{"id":"2662258722","title":"艾美疫苗午前涨逾16% 个性化mRNA宫颈癌治疗疫苗即将申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2662258722","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662258722?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:34","pubTimestamp":1787801640,"startTime":"0","endTime":"0","summary":"Moderna mRNA癌症疫苗III期临床取得里程碑式成功，引爆全球mRNA赛道行情。其中，个性化mRNA宫颈癌治疗疫苗即将申报临床。据艾美疫苗副总裁张凡介绍，艾美布局癌症疫苗近十年，是国内最早布局mRNA癌症疫苗的企业。艾美目前取得14个国内、国际mRNA疫苗的临床批件，是国内获得mRNA疫苗临床批件最多的公司。其中，mRNA带状疱疹疫苗，mRNA RSV疫苗已获批在中美两国开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-27/doc-iniptnux5485501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159646","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722987","title":"港股异动 | 艾美疫苗(06660.HK)早盘涨超17% 个性化mRNA宫颈癌治疗疫苗即将申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722987?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:22","pubTimestamp":1787800929,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661247425","title":"跌跌不休的艾美疫苗：5年半累亏近34亿元，营收一半用于营销","url":"https://stock-news.laohu8.com/highlight/detail?id=2661247425","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661247425?lang=zh_cn&edition=full","pubTime":"2026-08-24 11:02","pubTimestamp":1787540546,"startTime":"0","endTime":"0","summary":"8月23日晚间，港股艾美疫苗（06660）发布截至2026年6月30日止六个月的业绩。上半年实现收入3.51亿元，同比下降31.87%；母公司拥有者应占亏损为1.23亿元，同比下降6.32%。收入下降的主要原因包括国家增值税政策调整、行业舆情影响、市场竞争加剧以及采购周期变化。财报显示，公司二类疫苗和一类疫苗收入均有所下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608243850883210.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608243850883210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661924157","title":"艾美疫苗(06660)迭代工艺高效价人二倍体狂苗提交上市注册申请，技术优势领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2661924157","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661924157?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:08","pubTimestamp":1787530111,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾美疫苗8月24日公告，公司自主研发的迭代工艺高效价人二倍体狂犬疫苗已向国家药品监督管理局提交上市注册申请。根据已完成揭盲的Ⅲ期临床试验结果显示，艾美的迭代工艺高效价人二倍体狂苗，具有良好的安全性、免疫原性和免疫持久性，免疫原性和免疫持久性优效于同类对照疫苗，所有指标全面达到临床试验预设的评价标准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661249195","title":"Moderna引爆mRNA癌症疫苗行情，低位龙头个股估值有望爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2661249195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661249195?lang=zh_cn&edition=full","pubTime":"2026-08-24 07:23","pubTimestamp":1787527418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Moderna 联合默沙东的个体化mRNA 癌症疫苗 III 期临床取得重大阳性结果，彻底点燃全球 mRNA 赛道投资热情。在众多本土企业当中，mRNA疫苗龙头企业艾美疫苗估值有望爆发。业内人士分析，艾美疫苗凭借成熟的 mRNA 技术底座、多元的预防 + 癌症疫苗管线矩阵、完备的产业化能力，未来有望在 mRNA 癌症疫苗赛道保持持续领先。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661248010","title":"艾美疫苗半年收入同比降31.87%，亏损1.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661248010","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661248010?lang=zh_cn&edition=full","pubTime":"2026-08-23 19:45","pubTimestamp":1787485500,"startTime":"0","endTime":"0","summary":"8月23日，艾美疫苗（06660）发布截至2026年6月30日止六个月的业绩。公司在此期间的收入为3.51亿元，较2025年同期的5.15亿元下降31.87%。毛利为2.46亿元，同比下降27.98%。母公司拥有者应占亏损为1.23亿元。收入下降的主要原因包括国家增值税政策调整、行业舆情影响、市场竞争加剧以及采购周期变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608233850366984.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608233850366984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661248202","title":"艾美疫苗：上半财年营收3.51亿元人民币，同比下降31.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661248202","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661248202?lang=zh_cn&edition=full","pubTime":"2026-08-23 19:04","pubTimestamp":1787483043,"startTime":"0","endTime":"0","summary":"南财智讯8月23日电，艾美疫苗（06660.HK）公告，截至2026年6月30日止六个月，公司实现营业收入3.51亿元人民币，同比下降31.9%；毛利2.46亿元人民币，2025年同期为3.41亿元人民币；税前亏损1.32亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608233850362381.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608233850362381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03086","09834","03069","BK1515","07266","BK1147","01952","03455","BK4585","BK1585","07568","07261","02171","07522","KCAI","BK1191","VXUS","02834","BK1587","09086","BK1574","BK1161","VGT","07666","XLK","03034","TTTN","BK1583","BK4588","06660","06185","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184205412","title":"艾美疫苗(06660)公告将于2026年9月7日召开临时股东会审议定向增发等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1184205412","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184205412?lang=zh_cn&edition=full","pubTime":"2026-08-18 23:00","pubTimestamp":1787065239,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司(06660)8月18日发布公告称，公司将于2026年9月7日14时在中国上海市浦东新区陆家嘴街道丰和路1号港务大厦10楼会议室召开2026年第二次临时股东大会，就定向发行境内未上市股份方案等议案进行审议表决。所有议案将以投票方式进行表决。 ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182782869","title":"艾美疫苗(06660)拟修订境内未上市股份发行方案 最低募资4,280.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182782869","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182782869?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:41","pubTimestamp":1787064111,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司8月18日公告称，董事会已通过修订后的特定授权，计划在境内非公开发行不少于40,000,000股且不多于80,000,000股境内未上市股份，发行价格由原每股人民币3.0元至8.0元调整为每股人民币1.07元。发行对象由不超过35名调整为2名已确定对象及不超过33名待确定对象，其余主要条款不变。根据新方案，公司已与关联方西藏渤海投资集团有限公司签署《西藏渤海认购协议》。西藏渤海将以每股人民币1.07元认购37,383,178股，认购金额为4,000.00万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168932309","title":"艾美疫苗(06660)董事会将于8月23日审议2026年中期业绩及派息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1168932309","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168932309?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:22","pubTimestamp":1786530122,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司12日公告称，公司董事会会议拟于2026年8月23日（星期日）召开，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并将同步考虑建议派发中期股息（如有）及处理其他事项。公司并强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，也不对其准确性或完整性作出任何声明，且明确表示概不对因本公告全部或任何部分内容而引致的任何损失承担任何责任。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184422192","title":"艾美疫苗更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184422192","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184422192?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:55","pubTimestamp":1785833755,"startTime":"0","endTime":"0","summary":"2026年8月4日，艾美疫苗股份有限公司（股票代码：06660）发布截至2026年7月31日的证券变动月报。报告显示，本月公司注册股本合计为人民币1,226,562,599元，较上月无增减。\n具体来看，H股已发行股份（不含库存股）数量维持在507,673,711股，内资股已发行股份数量维持在718,888,888股，均无新增发行、购回或注销。公司也未发生库藏股及股份期权、权证、可换股票据等与股本相关的变动。\n截至报告期末，公司股本总数继续保持稳定，艾美疫苗确认已遵守香港联合交易所有限公司《上市规则》及相关法律规定。公告由公司秘书刘灵签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190809189","title":"艾美疫苗(06660)无血清迭代狂犬病疫苗注册进程迈入关键阶段 已向药监部门提交补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=1190809189","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190809189?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:05","pubTimestamp":1785715532,"startTime":"0","endTime":"0","summary":"2026年8月3日，艾美疫苗股份有限公司发布自愿性公告称，其全资子公司艾美荣誉（宁波）生物制药有限公司已就自主研发的无血清迭代狂犬病疫苗完成上市注册发补资料的提交，标志着该产品注册申报工作取得重要进展。艾美疫苗的新产品在生产过程中不添加任何动物血清组分，可从源头降低不良反应发生概率。\\n\\n艾美疫苗在公告中称，公司目前为全球第二大狂犬病疫苗供应商，将持续推动相关技术升级，并在产品获批后加速商业化投放。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194659193","title":"艾美疫苗6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1194659193","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194659193?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:15","pubTimestamp":1782983750,"startTime":"0","endTime":"0","summary":"艾美疫苗于2026年7月2日发布截至2026年6月30日的股份变动月报。报告显示，公司注册股本合计1,226,562,599元人民币，包括H股507,673,711股、内资股718,888,888股，面值均为每股人民币1元。上述注册股本数量与上月底保持一致。期权及股权激励计划也无相关增减记录。截至本月末，公司股本总额未发生变动，维持稳定。本次公告由公司秘书刘灵签署。公司表示将持续披露后续股本变动信息。期待进一步加强与投资者的沟通与信息交流。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442147","title":"艾美疫苗(06660)：吴季南已获委任为执行总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442147","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642442147?lang=zh_cn&edition=full","pubTime":"2026-06-10 21:52","pubTimestamp":1781099566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗 发布公告，有关委任刘灵女士(刘女士)为本公司执行董事，以及委任欧阳辉先生和邵伟才先生(邵先生)为本公司独立非执行董事的决议案，已于股东周年大会上获股东正式通过，并自股东周年大会结束时起生效。吴季南先生(吴先生)已获委任为本公司执行总裁、首席科学家兼研发管理委员会主任，并将负责本公司的研发及相关工作。吴先生的任期自2026年6月10日起，并于第二届董事会届满时结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾美疫苗(06660)：吴季南已获委任为执行总裁","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120361141","title":"艾美疫苗暂停mRNA人用狂犬疫苗项目并调减PCV13收入预测，整体减少研发开支约2.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120361141","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120361141?lang=zh_cn&edition=full","pubTime":"2026-06-05 22:37","pubTimestamp":1780670260,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司于2026年6月5日就截至2025年12月31日止年度的业绩情况进行了补充披露。公司在综合评估相关mRNA人用狂犬疫苗和mRNA兽用狂犬疫苗的短期研发可行性后，决定暂停推进mRNA人用狂犬疫苗项目，并在减值测试的现金流量预测中相应剔除上述疫苗的收入贡献，使收购产生的递延开发成本估值减少约人民币1.28亿元。另外，受PCV13商业化延迟及相应开发开支加大的影响，公司确认肺炎球菌疫苗相关长期资产减值损失约3.15亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"艾美疫苗暂停mRNA人用狂犬疫苗项目并调减PCV13收入预测，整体减少研发开支约2.10亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124673456","title":"艾美疫苗5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1124673456","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124673456?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:45","pubTimestamp":1780479939,"startTime":"0","endTime":"0","summary":"2026年6月3日，艾美疫苗股份有限公司发布截至2026年5月31日的股份变动月报表。公告显示，公司注册股本合计人民币1,226,562,599元，当期内未发生增发、购回、注销或库藏股等股份变动，股本保持稳定，公共持股量符合香港联交所《上市规则》相关要求。公告同时确认，公司在相关发行及变动中均遵守了监管机构的相关要求和法律法规，并已获得董事会授权。联交所信息显示，艾美疫苗当前公共持股比例符合最低公众持股要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636072799","title":"艾美疫苗(06660)：文洁辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2636072799","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636072799?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:24","pubTimestamp":1779117859,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗(06660)发布公告，文洁女士(文女士)因工作安排变动，已辞任独立非执行董事、本公司审计委员会(审计委员会)成员、本公司薪酬与考核委员会成员及本公司提名委员会成员，自新任独立非执行董事于将在2026年6月10日举行的本公司股东周年大会(股东周年大会)上获本公司股东选举起生效。于文女士辞任后，待将于股东周年大会上通过有关增加董事会的董事会成员人数的组织章程细则建议修订的特别决议案后，董事会已议决提名刘灵女士(刘女士)为执行董事，以及提名欧阳辉先生(欧阳先生)及邵伟才先生(邵先生)为本公司独立非执行董事，就此将于股东周年大会上提呈普通决议案供股东审议及批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161887124","title":"艾美疫苗拟回购最多10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1161887124","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161887124?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:55","pubTimestamp":1779116144,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司公告称，其董事会已决议建议向股东大会申请一般性授权，以回购不超过于股东大会批准当日已发行且尚未回购H股总数10%的股份。根据公告，董事会认为适度回购股权将有助于改善每股资产净值和每股收益水平，并认为此举符合公司及股东的最佳利益。公司H股股份过户登记将于2026年6月5日至6月10日期间暂停办理，股权登记日为6月10日。完成回购的H股将同时注销，公司注册资本相应调减。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾美疫苗拟回购最多10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01783","01833","81024","03692","03888","06060","09699","02256","02013","00013","01548","00719","02096","09858","09992","06660","02276","06049","02618","01357","02192","09688","01951","01952","06963","09626","03700","01440","00762","00169","09888","06969","06996","00909","02285","01024","02171","06160","06186","02126","01060","01905","02158","00136","02252","00772","06609","02172","02197","02306"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aimbio.com","stockEarnings":[{"period":"1week","weight":0.0654},{"period":"1month","weight":0.1875},{"period":"3month","weight":-0.2629},{"period":"6month","weight":-0.4184},{"period":"1year","weight":-0.6489},{"period":"ytd","weight":-0.4673}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.0123},{"period":"3month","weight":-0.0181},{"period":"6month","weight":0.0126},{"period":"1year","weight":0.0195},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸（mRNA）新冠（COVID-19）疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.052664},{"month":2,"riseRate":0.5,"avgChangeRate":0.02733},{"month":3,"riseRate":0.5,"avgChangeRate":0.138475},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094553},{"month":5,"riseRate":0.5,"avgChangeRate":0.029763},{"month":6,"riseRate":0.25,"avgChangeRate":-0.09386},{"month":7,"riseRate":0.5,"avgChangeRate":0.035575},{"month":8,"riseRate":0.75,"avgChangeRate":-0.017257},{"month":9,"riseRate":0.333333,"avgChangeRate":0.144896},{"month":10,"riseRate":0,"avgChangeRate":-0.306447},{"month":11,"riseRate":0,"avgChangeRate":-0.121084},{"month":12,"riseRate":0.25,"avgChangeRate":-0.055586}],"exchange":"SEHK","name":"艾美疫苗","nameEN":"AIM VACCINE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾美疫苗,06660,艾美疫苗股票,艾美疫苗股票老虎,艾美疫苗股票老虎国际,艾美疫苗行情,艾美疫苗股票行情,艾美疫苗股价,艾美疫苗股市,艾美疫苗股票价格,艾美疫苗股票交易,艾美疫苗股票购买,艾美疫苗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}